Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India

Autor: J.K Lazdins-Helds, V.S Kadam, Nilima A Kshirsagar, Arpit Gupta, Pradeep R Deshmukh, D. D. Rajgor, Nithya J Gogtay, Bishan S Garg, P. A. Thakur, N.S Ingole
Rok vydání: 2017
Předmět:
Adult
Male
medicine.medical_specialty
Adult worm
030231 tropical medicine
India
Albendazole
Microfilaria
Gastroenterology
Diethylcarbamazine
Drug Administration Schedule
03 medical and health sciences
0302 clinical medicine
Elephantiasis
Filarial
Double-Blind Method
health services administration
Internal medicine
parasitic diseases
medicine
Prevalence
Animals
Humans
Wuchereria bancrofti
030212 general & internal medicine
Longitudinal Studies
Mass drug administration
health care economics and organizations
Lymphatic filariasis
General Veterinary
business.industry
Drug administration
General Medicine
medicine.disease
Infectious Diseases
Filaricides
Tolerability
Insect Science
Antigens
Helminth
Immunology
population characteristics
Parasitology
Drug Therapy
Combination
Female
business
geographic locations
medicine.drug
Zdroj: Parasitology research. 116(10)
ISSN: 1432-1955
Popis: Lymphatic filariasis (LF) affects 73 countries, causes morbidity and impedes socioeconomic development. We had found no difference in safety and micro (Mf) and macro filarial action of single-dose diethylcarbamazine (DEC) and DEC + albendazole (ABZ) in an F01 study done in India (year 2000). There was a programmatic need to evaluate safety and efficacy of multiple annual treatments (F02). Subjects (155) from the F01 study, meeting inclusion-exclusion criteria, were enrolled in F02 and treated with further two annual doses of DEC or DEC + ABZ. Efficacy was evaluated for Mf positivity by peripheral smear (PS) and nucleopore (NP) filter, circulating filarial antigen (CFA) and filarial dance sign (FDS) positivity and Mf count at yearly follow-up. Safety was assessed for 5 days after drug administration. Total of 139 subjects evaluated for efficacy (69 DEC and 70 DEC + ABZ group). Mf positivity prevalence declined progressively by 95% (PS), 66% (NP), and 95% (PS) and 86% (NP); CFA positivity prevalence declined by 15% and 9%; FDS by 100% each; Mf count declined by 75.5 and 76.9% with three annual treatment of DEC and DEC + ABZ, respectively. Addition of ABZ did not show any advantage over DEC given as three annual rounds for LF. DEC and DEC + ABZ were well tolerated. There was no correlation between result of CFA and FDS, (both claimed to be indicative of adult worm). Analysis of published studies and our data indicate that macrofilaricidal effect of DEC/DEC + ABZ may be seen in children and not adults, with three or more annual dosing.
Databáze: OpenAIRE
Externí odkaz: